MGTA-45

About Magenta Therapeutics

Magenta Therapeutics' mission was to re-engineer the stem cell transplantation process to make it safer, more effective, and accessible. The company developed a pipeline of targeted antibody-drug conjugates (ADCs) and small molecules focused on conditioning, mobilization, and immune reconstitution. Despite significant early promise and capital investment, its lead clinical programs failed to demonstrate sufficient efficacy in Phase 2 trials in 2023, leading to strategic wind-down and asset acquisition.

Therapeutic Areas